Benefits of molecular profiling with next-generation sequencing for the diagnosis and prognosis of myeloproliferative neoplasms in splanchnic vein thrombosis

[:en]

Next Generation Sequencing (NGS) has become a diagnostic tool for many oncological diseases. Its interest was recently underlined for the diagnosis of myeloproliferative syndrome, in patients with splanchnic venous thrombosis without cirrhosis. Through a collaboration between Beaujon hospital and Saint Louis hospital, PE Rautou and Jean-Jacques Kiladjian have shown that molecular profiling of these patients allows the identification of patients who are at high risk of malignant transformation and whose prognosis is darker. This makes NGS not only a diagnostic tool but also a theranostic.

[:]